These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26410247)

  • 1. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
    Lexchin J
    Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
    Lexchin J
    Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
    Lexchin J
    CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between FDA black box warnings and Medicare formulary coverage changes.
    Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
    Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ontario's formulary committee: how recommendations are made.
    PausJenssen AM; Singer PA; Detsky AS
    Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
    Lexchin J
    BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How complete are drug history profiles that are based on public drug benefit claims?
    Paterson JM; Suleiman A; Hux JE; Bell C
    Can J Clin Pharmacol; 2008; 15(1):e108-16. PubMed ID: 18283220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced ocular adverse reactions: review of the safety alerts issued during the last decade.
    Penedones A; Mendes D; Alves C; Marques FB
    J Ocul Pharmacol Ther; 2015 Jun; 31(5):258-68. PubMed ID: 25871404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.
    Grootendorst P; Shim M; Falconi A; Robinson T; Lexchin J
    Int J Health Serv; 2018 Oct; 48(4):702-715. PubMed ID: 30040005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
    Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
    Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
    Lexchin J
    Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulary decisions for pre-1938 medications.
    Culley CM; Carroll BA; Skledar SJ
    Am J Health Syst Pharm; 2008 Jul; 65(14):1363-7. PubMed ID: 18593683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentially inappropriate prescribing in Canada relative to the US.
    Rochon PA; Lane CJ; Bronskill SE; Sykora K; Anderson GM; Mamdani MM; Gurwitz JH; Dhalla IA
    Drugs Aging; 2004; 21(14):939-47. PubMed ID: 15554752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.